App-Based Education and Low-Residue Diet for Colonoscopy Preparation

February 1, 2026 updated by: Chen-Ming Hsu, Chang Gung Memorial Hospital

Impact of App-Based Education and Low-Residue Diet Approaches on Colonoscopy Preparation in Naive Patients: A Randomized, Evaluator-Blind Controlled Trial

This prospective, randomized, evaluator-blind, parallel-group trial is designed to objectively compare the effectiveness of Advanced Bowel Preparation versus Traditional Bowel Preparation in patients undergoing colonoscopy. In this study, "naive patients" are defined as individuals who have never used Bowklean® as a bowel cleansing agent, or those who may have previously used other bowel preparation regimens but have not undergone any bowel cleansing procedure within the past three years. The Traditional Bowel Preparation approach consists of standard paper-based educational handouts and self-managed low residue dietary restrictions. In contrast, the Advanced Bowel Preparation integrates a smartphone based educational app with a Prepackaged Low-Residue Diet. All participants will use Bowklean®, a bowel preparation agent combining sodium picosulfate, magnesium oxide, and anhydrous citric acid.

The primary endpoint is the percentage of subjects that achieve adequate cleansing (score ≧ 6) in the Boston Bowel Preparation Scale (BBPS).

The secondary endpoints include the percentage of subjects that achieve excellent cleansing (score ≧ 8) in the BBPS, mean score in different colon segments (right, transverse, left), which are assessed with the BBPS, adenoma detection rate, sessile serrated polyp detection rate, and patient satisfaction.

Study Overview

Detailed Description

Bowel preparation is a important task for colonoscopy examination. Studies have demonstrated that using smartphone apps can improve patient compliance and the quality of bowel cleansing. Additionally, the use of prepackaged low residue diet (PLD) has become increasingly common. PLD are designed to minimize undigested food residue in the gut, facilitating a cleaner colon for procedures like colonoscopy. Implementing PLD can reduce the burden of dietary restrictions on patients and enhance the effectiveness of bowel preparation. This study aims to evaluate whether an advanced bowel preparation protocol that combines a smartphone application with a PLD can improve patient satisfaction, and the cleanliness of the colon compared to standard preparation methods.

This prospective, randomized, evaluator-blind, parallel-group trial is designed to objectively compare the effectiveness of Advanced Bowel Preparation versus Traditional Bowel Preparation in patients undergoing colonoscopy. In this study, "naive patients" are defined as individuals who have never used Bowklean® as a bowel cleansing agent, or those who may have previously used other bowel preparation regimens but have not undergone any bowel cleansing procedure within the past three years. The Traditional Bowel Preparation approach consists of standard paper-based educational handouts and self-managed low residue dietary restrictions. In contrast, the Advanced Bowel Preparation integrates a smartphone based educational app (Tian Tian Yi Chi go, developed by UIC Corp.) with a Prepackaged Low-Residue Diet (PLD). All participants will use Bowklean®, a bowel preparation agent combining sodium picosulfate, magnesium oxide, and anhydrous citric acid. Blinding of outcome evaluators (endoscopists) helps minimize assessment bias, while the randomized parallel-arm design supports robust group comparisons. This design allows a focused assessment of whether combining digital and dietary support can improve bowel cleanliness, detection outcomes, and patient satisfaction. Overall, this trial structure is intended to generate clinically relevant, real-world evidence on optimizing colonoscopy preparation by integrating pharmacologic, digital, and dietary strategies.

Primary Endpoint:

The percentage of subjects that achieve adequate cleansing (score ≧ 6) in the Boston Bowel Preparation Scale (BBPS).

The secondary endpoints include:

The percentage of subjects that achieve excellent cleansing (score ≧ 8) in the Boston Bowel Preparation Scale (BBPS).

Mean score in different colon segments (right, transverse, left), which are assessed with the BBPS.

Adenoma Detection Rate (ADR): Proportion of patients in whom at least one adenoma is detected during the colonoscopy.

Sessile Serrated Polyp (SSP) Detection Rate: Proportion of patients in whom at least one SSP is detected during the colonoscopy.

Patient Satisfaction: Satisfaction will be evaluated in three subcategories through a questionnaire:

  1. Bowel cleansing agent: Assessing the experience and acceptability of using Bowklean.
  2. Dietary restrictions: Evaluating satisfaction with the assigned low-residue dietary approach (PLD or self-prepared).
  3. APP Satisfaction: For groups assigned to APP utilization, assessing the APP's ease of use, functionality, and perceived utility. 0800 Toll-Free Analysis

Safety Endpoints: Percentage of subjects occurred solicited events from the start of administration of study medications before colonoscopy. Percentage of subjects with treatment-emergent adverse events during the study period.

Eligible participants will be randomly assigned in a 1:1 ratio to one of two groups: Advanced Bowel Preparation (Group A): Participants will receive a PLD along with an APP based educational platform ( Tian Tian Yi Chi go) and Traditional Bowel Preparation (Group B).

Subject Population Assuming an acceptable bowel preparation rate of 70% for Traditional Bowel Preparation and 90% for Advanced Bowel Preparation, a significance level (α) of 0.05, statistical power of 80%, Single tailed test, and accounting for a 10% dropout rate, approximately 207 subjects per group (total 420 subjects) are required.

Inclusion Criteria Male or female 18 to 75 years of age. Bowklean naive patient with no bowel preparation in 3 years. The subject is scheduled for a colonoscopy. Ability to complete the entire procedure and to comply with study instructions. Willingness and ability to provide signed informed consent.

Exclusion Criteria Patients who are unsuitable for Bowklean use due to known contraindications, including but not limited to: (1) Allergies or hypersensitivity to Bowklean or its ingredients. (2) Severe gastrointestinal conditions (e.g., obstruction, perforation). (3) Renal impairment or electrolyte imbalances (e.g., severe hyponatremia). (4) Gastrointestinal surgery affects bowel preparation. Patients deemed medically unsuitable for colonoscopy by the physician. Cognitive, language, or other barriers that prevent completion of the questionnaire. Non-compliance with the bowel preparation protocol or inability to follow dietary restrictions (e.g., Prepackaged low residue diet, PLD). Inability to use or access the mobile APP (e.g., no smartphone, unfamiliarity with APP operations, or technical limitations). Participation in other clinical trials.

Discontinuation Criteria of Subjects Discontinuation is a subject who is randomized into the study and for whom study medication (Group A or Group B) is terminated prematurely for any reason. The subject is free to withdraw from the study for any reason and at any time without giving reason for doing so and without penalty or prejudice.

Study Type

Interventional

Enrollment (Estimated)

420

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Male or female 18 to 75 years of age.
  2. Bowklean naive patient with no bowel preparation in 3 years.
  3. The subject is scheduled for a colonoscopy.
  4. Ability to complete the entire procedure and to comply with study instructions.
  5. Willingness and ability to provide signed informed consent.

Exclusion Criteria:

1. Patients who are unsuitable for Bowklean use due to known contraindications, including but not limited to:

  1. Allergies or hypersensitivity to Bowklean or its ingredients.
  2. Severe gastrointestinal conditions (e.g., obstruction, perforation).
  3. Renal impairment or electrolyte imbalances (e.g., severe hyponatremia).
  4. Gastrointestinal surgery affects bowel preparation. 2. Patients deemed medically unsuitable for colonoscopy by the physician. 3. Cognitive, language, or other barriers that prevent completion of the questionnaire.

4. Non-compliance with the bowel preparation protocol or inability to follow dietary restrictions (e.g., Prepackaged low residue diet, PLD).

5. Inability to use or access the mobile APP (e.g., no smartphone, unfamiliarity with APP operations, or technical limitations).

6. Participation in other clinical trials.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Traditional Bowel Preparation
The Traditional Bowel Preparation approach consists of standard paper-based educational handouts and self-managed low-residue dietary restrictions.
Experimental: Advanced Bowel Preparation
Advanced Bowel Preparation integrates a smartphone-based educational app (Tian Tian Yi Chi go, developed by UIC Corp.) with a Prepackaged Low-Residue Diet (PLD).
Bowl preparation educational app
Prepackaged Low-Residue Diet

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of subjects that achieve adequate cleansing
Time Frame: Day1
The percentage of subjects that achieve adequate cleansing (score ≧ 6) in the Boston Bowel Preparation Scale (BBPS)
Day1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The percentage of subjects that achieve excellent cleansing
Time Frame: Day1
(score ≧ 8) in the Boston Bowel Preparation Scale (BBPS).
Day1
Mean score in different colon segments
Time Frame: Day1
right, transverse, left colon segmental subscore, which are assessed with the BBPS.
Day1
Adenoma Detection Rate (ADR)
Time Frame: Day14
Proportion of patients in whom at least one adenoma is detected during the colonoscopy.
Day14
Sessile Serrated Polyp (SSP) Detection Rate
Time Frame: Day14
Proportion of patients in whom at least one SSP is detected during the colonoscopy.
Day14
Patient Satisfaction
Time Frame: Day1

Satisfaction will be evaluated in three subcategories through a questionnaire:

  1. Bowel cleansing agent: Assessing the experience and acceptability of using Bowklean.
  2. Dietary restrictions: Evaluating satisfaction with the assigned low-residue dietary approach (PLD or self-prepared).
  3. APP Satisfaction: For groups assigned to APP utilization, assessing the APP's ease of use, functionality, and perceived utility.
Day1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 1, 2026

Primary Completion (Estimated)

October 21, 2026

Study Completion (Estimated)

October 21, 2026

Study Registration Dates

First Submitted

December 17, 2025

First Submitted That Met QC Criteria

February 1, 2026

First Posted (Actual)

February 9, 2026

Study Record Updates

Last Update Posted (Actual)

February 9, 2026

Last Update Submitted That Met QC Criteria

February 1, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 202501149B0

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bowel Preparation Solution

Subscribe